Abstract

BackgroundThe expansion of access to antiretroviral therapy (ART) has been accompanied by an increase in pre-treatment drug resistance (PDR). While it is critical to monitor the increasing prevalence of PDR across countries and populations to inform optimal regimen selection, the completeness of reporting is often suboptimal, limiting the interpretation and generalizability of the results. Indeed, there is no formal guidance on how studies investigating the prevalence of drug resistance should be reported. Thus, we sought to determine the completeness of reporting in studies of PDR and the factors associated with sub-optimal reporting to ascertain the need for guidelines.MethodsAs part of a systematic review on the global prevalence of PDR in key populations (men who have sex with men, sex workers, transgender people, people who inject drugs and people in prisons), we searched 10 electronic databases until January 2019. We extracted information on selected study characteristics useful for interpreting prevalence data. Data were extracted in duplicate. Analyses of variance and correlation were used to explore factors that may explain the number of items reported.ResultsWe found 650 studies of which 387 were screened as full text and 234 were deemed eligible. The included studies were published between 1997 and 2019 and included a median of 239 (quartile 1 = 101; quartile 3 = 778) participants. Most studies originated from high-income countries (125/234; 53.0%). Of 23 relevant data items, including study design, setting, participant sociodemographic characteristics, HIV risk factors, type of resistance test conducted, definition of resistance, the mean (standard deviation) number of items reported was 13 (2.2). We found that more items were reported in studies published more recently (r = 0.20; p < 0.002) and in studies at low risk of bias (F [2231] = 8.142; p < 0.001).ConclusionsIncomplete reporting in studies on PDR makes characterising levels of PDR in subpopulations across countries challenging. Hence, guidelines are needed to define a minimum set of variables to be included in such studies.

Highlights

  • The expansion of access to antiretroviral therapy (ART) has been accompanied by an increase in pretreatment drug resistance (PDR)

  • While Human immunodeficiency virus (HIV) incidence has decreased over the years, the large number of people living with HIV can be attributed to improvements in the management of HIV infection by early detection and early treatment with antiretroviral therapy (ART)

  • PDR can be due to infection with a drug resistant viral strain, referred to as transmitted drug resistance, or due to prior exposure to antiretroviral treatment

Read more

Summary

Introduction

The expansion of access to antiretroviral therapy (ART) has been accompanied by an increase in pretreatment drug resistance (PDR). While HIV incidence has decreased over the years, the large number of people living with HIV can be attributed to improvements in the management of HIV infection by early detection and early treatment with antiretroviral therapy (ART). Drug resistant viral strains are already present prior to ART initiation. This is referred to as pre-treatment drug resistance (PDR). PDR can be due to infection with a drug resistant viral strain, referred to as transmitted drug resistance, or due to prior exposure to antiretroviral treatment (e.g., women and children exposed to treatment as part of prevention of vertical transmission programs and people who abandoned prior treatments)

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call